Voyager Says Joint Steering Committee With Collaborator Neurocrine Selected A Development Candidate In Gene Therapy Program; Selection Of Candidate Triggered $3M Milestone Payment
Portfolio Pulse from Benzinga Newsdesk
Voyager Therapeutics and Neurocrine Biosciences have selected a development candidate in their gene therapy program, triggering a $3 million milestone payment to Voyager. Voyager is eligible for further milestone payments and royalties under their collaboration agreement.
September 16, 2024 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences, in collaboration with Voyager, has selected a development candidate in their gene therapy program. Neurocrine will fund the development, potentially leading to future milestone payments and royalties.
Neurocrine's collaboration with Voyager progresses with the selection of a development candidate, which could lead to future milestone payments and royalties, indicating potential growth in their gene therapy portfolio.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
Voyager Therapeutics has selected a development candidate in its gene therapy program with Neurocrine, triggering a $3M milestone payment. Voyager stands to gain further milestone payments and royalties as the program progresses.
The selection of a development candidate in the gene therapy program with Neurocrine triggers a $3M payment to Voyager, indicating progress and potential future revenue streams. This is positive news for Voyager, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90